Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Medicine, University of Pennsylvania, Perelman School of Medicine at University of Pennsylvania, 3600 Spruce Street, 3 Maloney Building, Philadelphia, PA 19104, USA.
Neuron. 2024 Sep 25;112(18):3029-3042. doi: 10.1016/j.neuron.2024.05.017. Epub 2024 Jun 10.
The aggregation of alpha-synuclein (aSyn) represents a neuropathological hallmark observed in a group of neurodegenerative disorders collectively known as synucleinopathies. Despite their shared characteristics, these disorders manifest diverse clinical and pathological phenotypes. The mechanism underlying this heterogeneity is thought to be due to the diversity in the aSyn strains present across the diseases. In this perspective, we will explore recent findings on aSyn strains and discuss recent discoveries about Lewy bodies' composition. We further discuss the current hypothesis for aSyn spreading and emphasize the emerging biomarker field demonstrating promising results. A comprehension of these mechanisms holds substantial promise for future clinical applications. This understanding can pave the way for the development of personalized medicine strategies, specifically targeting the unique underlying causes of each synucleinopathy. Such advancements can revolutionize therapeutic approaches and significantly contribute to more effective interventions in the intricate landscape of neurodegenerative disorders.
α-突触核蛋白(aSyn)的聚集代表了一组被称为突触核蛋白病的神经退行性疾病中观察到的神经病理学标志。尽管它们具有共同的特征,但这些疾病表现出不同的临床和病理表型。这种异质性的机制被认为是由于疾病中存在的 aSyn 菌株的多样性。在这篇观点文章中,我们将探讨 aSyn 菌株的最新发现,并讨论关于路易体组成的最新发现。我们进一步讨论 aSyn 传播的当前假设,并强调具有有前途结果的新兴生物标志物领域。对这些机制的理解为未来的临床应用提供了巨大的希望。这种理解为开发针对每个突触核蛋白病独特潜在原因的个性化医学策略铺平了道路。这些进展可以彻底改变治疗方法,并为神经退行性疾病复杂领域中的更有效干预做出重大贡献。